Drugs / Lrinotecan liposome
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06592287 | Sep 2024 → Sep 2025 overdue | gastric cancer | Xianglin Yuan | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lrinotecan liposome | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06592287 ↗ |
| Route | Intravenous | “Lrinotecan liposome 80mg/m2, iv. q3w” NCT06592287 ↗ |